Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIJ821 (Onfasprodil) Receptor Occupancy Study
NCT05666687Phase 1Completed
- Sponsor
- Novartis
- Start
- Jan 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of onfasprodil in major depressive disorder (MDD) and treatment-resistant depression (TRD) (5 cohorts), sponsored by Novartis. Primary endpoints: Human Brain Receptor Occupancy and Plasma Concentration of MIJ821. Started Jan 2023; status: completed.
02
Drugs
onfasprodil
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05666687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666687.